Partners & Collaborators

Strategic Agreements

We have developed important strategic agreements and contractual relationships with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. Our relationships have included:

University of California, San Francisco (UCSF)

We entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics, Inc.’s (a wholly-owned subsidiary of Shuttle Pharma) ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. UCSF researchers, led by principal investigator, Robert Flavell, M.D., PhD., will aim to develop radiosynthetic methods for producing [¹⁸F]FPA-ACUPA probe; investigate cellular binding properties of [¹⁸F]FPA-ACUPA in PCa cell lines; and investigate the diagnostic potential of the probe across various PCa phenotypes. Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application with the US Patent and Trademark Office.

Georgetown University

Georgetown University is an internationally recognized educational and research university engaged in the discovery and development of new cancer diagnostics and therapeutics through the programs of the Lombardi Comprehensive Cancer Center. Shuttle Pharmaceuticals subcontracted clinical aspects of SBIR funded research to establish cancer cell lines from African-American patients and to develop predictive biomarkers for patient sensitivity to radiation late-effects.

Brown University

We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical trials of brain tumors, sarcomas and other tumors.

University of Virginia

The University of Virginia is an internationally recognized educational and research university engaged in the discovery and development of new cancer therapeutics and has developed the “Atomic Radiation” intellectual property. Shuttle Pharmaceuticals’ scientists collaborate with scientists at the University of Virginia to sensitizers for use with proton radiation therapy.

George Washington Cancer Center

Collaborations between the Villagra lab at George Washington University and the Shuttle Pharmaceuticals’ lab resulted in a joint presentation at the October 2020 AACR Conference of research addressing: “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225.” Dr. Villagra has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics and immunology since 2017. We also have a material transfer agreement for testing HDAC inhibitor effects in immune model systems

TCG GreenChem

TCG GreenChem Inc. is a sister company of TCG Lifesciences Pvt. Ltd. Both are a part of the TCG Group based in New York, NY and together a leading global Custom Research and Manufacturing Services (CRAMS) company for drug discovery, development and commercialization. They have a presence in the United States, India, and Japan. TCG GreenChem Founder and Chief Executive Officer, Chris Senanayake, PhD along with Executive Vice President and Global Head of Research and Development, Executive Vice President and Global Head of Research and Development joined Shuttle’s leadership team in 2020 to manufacture drug product for use in proposed clinical trials.

For a list of our trial locations, please visit our Clinicals Trial Page.